1. Preface
     1.1. Market Definition and Scope
     1.2. Market Segmentation
     1.3. Key Research Objectives
     1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market

4. Market Overview
     4.1. Drug Class Overview
     4.2. Global MRSA Drugs Market Outlook

5. Market Dynamics
     5.1. Drivers
     5.2. Restraints
     5.3. Opportunities

6. Epidemiological Assessment of Methicillin-resistant Staphylococcus Aureus (MRSA)

7. MRSA Drugs: Pipeline Analysis

8. MRSA Drugs Market: Competitive Landscape of Key Players

9. Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market Analysis and Forecasts, By Drug Class 
     9.1. Introduction & Definition
     9.2. Key Findings / Developments
     9.3. Market Value Forecast By Drug Class, 2015–2025
            9.3.1. Lipopeptide
            9.3.2. Oxazolidinone
            9.3.3. Cephalosporin
            9.3.4. Tetracycline
            9.3.5. Lipoglycopeptide
            9.3.6. Folate Antagonist
            9.3.7. Others
     9.4. Market Attractiveness By Drug Class 
     9.5 Key Trends

10. Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market Analysis and Forecasts, By Route of Administration 
     10.1. Introduction & Definition
     10.2. Key Findings / Developments
     10.3. Market Value Forecast By Route of Administration, 2015–2025
            10.3.1. Oral
            10.3.2. Parenteral
     10.4. Market Attractiveness By Route of Administration 
     10.5. Key Trends

11. Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market Analysis and Forecasts, By Distribution Channel 
     11.1. Introduction & Definition
     11.2. Key Findings / Developments
     11.3. Market Value Forecast By Distribution Channel, 2015–2025
            11.3.1. Hospital Pharmacy
            11.3.2. Retail Pharmacy
            11.3.3. Online Pharmacy
     11.4. Market Attractiveness By Distribution Channel 
     11.5 Key Trends

12. Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market Analysis and Forecasts, By Region
     12.1. Key Findings
     12.2. Market Value Forecast By Region
            12.2.1. North America 
            12.2.2. Europe 
            12.2.3. Asia Pacific 
            12.2.4. Latin America 
            12.2.5. Middle East & Africa 
     12.3. Market Attractiveness By Country/Region

13. North America Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market Analysis and Forecast
     13.1. Introduction
            13.1.1. Key Findings
     13.2. Market Value Forecast By Drug Class, 2015–2025
            13.2.1. Lipopeptide
            13.2.2. Oxazolidinone
            13.2.3. Cephalosporin
            13.2.4. Tetracycline
            13.2.5. Lipoglycopeptide
            13.2.9. Folate Antagonist
            13.2.7. Others
     13.3. Market Value Forecast By Route of Administration, 2015–2025
            13.3.1. Oral
            13.3.2. Parenteral
     13.4. Market Value Forecast By Distribution Channel, 2015–2025
            13.4.1. Hospital Pharmacy
            13.4.2. Retail Pharmacy
            13.4.3. Online Pharmacy
     13.5. Market Value Forecast By Country, 2015–2025
            13.5.1. U.S.
            13.5.2. Canada
     13.6. Market Attractiveness Analysis 
            13.6.1. By Drug Class 
            13.6.2. By Route of Administration 
            13.6.3. By Distribution Channel 
            13.6.4. By Country

14. Europe Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market Analysis and Forecast
     14.1.Introduction
            14.1.1. Key Findings
     14.2.Market Value Forecast By Drug Class, 2015–2025
            14.2.1. Lipopeptide
            14.2.2. Oxazolidinone
            14.2.3. Cephalosporin
            14.2.4. Tetracycline
            14.2.5. Lipoglycopeptide
            14.2.6. Folate Antagonist
            14.2.7. Others
     14.3.Market Value Forecast By Route of Administration, 2015–2025
            14.3.1. Oral
            14.3.2. Parenteral
     14.4.Market Value Forecast By Distribution Channel, 2015–2025
            14.4.1. Hospital Pharmacy
            14.4.2. Retail Pharmacy
            14.4.3. Online Pharmacy
     14.5.Market Value Forecast By Country, 2015–2025
            14.5.1. Germany
            14.5.2. U.K.
            14.5.3. France
            14.5.4. Spain
            14.5.5. Italy
            14.5.6. Russia
            14.5.7. Rest of Europe
     14.6.Market Attractiveness Analysis 
            14.6.1. By Drug Class 
            14.6.2. By Route of Administration 
            14.6.3. By Distribution Channel 
            14.6.4. By Country

15. Asia Pacific Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market Analysis and Forecast
     15.1.Introduction
            15.1.1. Key Findings
     15.2.Market Value Forecast By Drug Class, 2015–2025
            15.2.1. Lipopeptide
            15.2.2. Oxazolidinone
            15.2.3. Cephalosporin
            15.2.4. Tetracycline
            15.2.5. Lipoglycopeptide
            15.2.6. Folate Antagonist
            15.2.7. Others
     15.3.Market Value Forecast By Route of Administration, 2015–2025
            15.3.1. Oral
            15.3.2. Parenteral
     15.4.Market Value Forecast By Distribution Channel, 2015–2025
            15.4.1. Hospital Pharmacy
            15.4.2. Retail Pharmacy
            15.4.3. Online Pharmacy
     15.5.Market Value Forecast By Country, 2015–2025
            15.5.1. China
            15.5.2. Japan
            15.5.3. India
            15.5.4. Australia & New Zealand
            15.5.5. Rest of Asia Pacific
     15.6.Market Attractiveness Analysis 
            15.6.1. By Drug Class 
            15.6.2. By Route of Administration 
            15.6.3. By Distribution Channel 
            15.6.4. By Country

16. Latin America Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market Analysis and Forecast
     16.1.Introduction
            16.1.1. Key Findings
     16.2.Market Value Forecast By Drug Class, 2015–2025
            16.2.1. Lipopeptide
            16.2.2. Oxazolidinone
            16.2.3. Cephalosporin
            16.2.4. Tetracycline
            16.2.5. Lipoglycopeptide
            16.2.6. Folate Antagonist
            16.2.7. Others
     16.3.Market Value Forecast By Route of Administration, 2015–2025
            16.3.1. Oral
            16.3.2. Parenteral
     16.4.Market Value Forecast By Distribution Channel, 2015–2025
            16.4.1. Hospital Pharmacy
            16.4.2. Retail Pharmacy
            16.4.3. Online Pharmacy
     16.5.Market Value Forecast By Country, 2015–2025
            16.5.1. Brazil
            16.5.2. Mexico
            16.5.3. Rest of Latin America
     16.6.Market Attractiveness Analysis 
            16.6.1. By Drug Class 
            16.6.2. By Route of Administration 
            16.6.3. By Distribution Channel 
            16.6.4. By Country

17. Middle East & Africa Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market Analysis and Forecast
     17.1.Introduction
            17.1.1. Key Findings
     17.2.Market Value Forecast By Drug Class, 2015–2025
            17.2.1. Lipopeptide
            17.2.2. Oxazolidinone
            17.2.3. Cephalosporin
            17.2.4. Tetracycline
            17.2.5. Lipoglycopeptide
            17.2.6. Folate Antagonist
            17.2.7. Others
     17.3.Market Value Forecast By Route of Administration, 2015–2025
            17.3.1. Oral
            17.3.2. Parenteral
     17.4.Market Value Forecast By Distribution Channel, 2015–2025
            17.4.1. Hospital Pharmacy
            17.4.2. Retail Pharmacy
            17.4.3. Online Pharmacy
     17.5.Market Value Forecast By Country, 2015–2025
            17.5.1. GCC Countries
            17.5.2. South Africa
            17.5.3. Israel
            17.5.4. Rest of Middle East & Africa
     17.6.Market Attractiveness Analysis 
            17.6.1. By Drug Class 
            17.6.2. By Route of Administration 
            17.6.3. By Distribution Channel 
            17.6.4. By Country

18. Competition Landscape
     18.1.Market Player – Competition Matrix (By Tier and Size of companies)
     18.2.Market Share Analysis By Company (2016)
     18.3. Company Profiles
            18.5.1. Basilea Pharmaceutica Ltd.
                      18.3.1.1. Overview
                      18.3.1.2.Financials
                      18.3.1.3.Recent Developments
                      18.3.1.4.SWOT Analysis
                      18.3.1.5.Strategic Overview
            18.3.2. The Medicines Company
                      18.3.2.1. Overview
                      18.3.2.2.Financials
                      18.3.2.3.Recent Developments
                      18.3.2.4.SWOT Analysis
                      18.3.2.5.Strategic Overview
            18.3.3. Theravance Biopharma
                      18.3.3.1. Overview
                      18.3.3.2.Financials
                      18.3.3.3.Recent Developments
                      18.3.3.4.SWOT Analysis
                      18.3.3.5.Strategic Overview
            18.3.4. Allergan
                      18.3.4.1. Overview
                      18.3.4.2.Financials
                      18.3.4.3.Recent Developments
                      18.3.4.4.SWOT Analysis
                      18.3.4.5.Strategic Overview
            18.3.5. Merck & Co., Inc.
                      18.3.5.1. Overview
                      18.3.5.2.Financials
                      18.3.5.3.Recent Developments
                      18.3.5.4.SWOT Analysis
                      18.3.5.5.Strategic Overview
            18.3.6. Pfizer, Inc.
                      18.3.6.1. Overview
                      18.3.6.2.Financials
                      18.3.6.3.Recent Developments
                      18.3.6.4.SWOT Analysis
                      18.3.6.5.Strategic Overview

List of Tables

Table 01 Global MRSA infection Prevalence (%), 2015
Table 02 Global MRSA infection Prevalence (%), 2015
Table 03 Global MRSA infection Prevalence (%), 2015
Table 04 MRSA Drugs: Pipeline Snapshot, 2016
Table 05 MRSA Drugs: Pipeline Snapshot, 2016
Table 06 MRSA Drugs: Competitive Landscape
Table 07 Global MRSA Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 08 Global MRSA Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2015–2025
Table 09 Global MRSA Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 10 Global MRSA Drugs Market Size (US$ Mn) Forecast, by Region, 2015–2025
Table 11 North America MRSA Drugs Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 12 North America MRSA Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 13 North America MRSA Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2015–2025
Table 14 North America MRSA Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 15 Europe MRSA Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 16 Europe MRSA Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 17 Europe MRSA Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2015–2025
Table 18 Europe MRSA Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 19 Asia Pacific MRSA Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 20 Asia Pacific MRSA Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 21 Asia Pacific MRSA Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2015–2025
Table 22 Asia Pacific MRSA Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 23 Latin America MRSA Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 24 Latin America MRSA Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 25 Latin America MRSA Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2015–2025
Table 26 Latin America MRSA Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 27 Middle East & Africa MRSA Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 28 Middle East & Africa MRSA Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 29 Middle East & Africa MRSA Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2015–2025
Table 30 Middle East & Africa MRSA Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025

List of Figures

Fig. 01 Global MRSA Drugs Market Size (US$ Mn) and Distribution (%) by Geography, 2017 and 2025
Fig. 02 Global MRSA Drugs Market Value Share, by Drug Class (2016)
Fig. 03 Global MRSA Drugs Market Value Share, by Route of Administration (2016)
Fig. 04 Global MRSA Drugs Market Value Share, by Distribution Channel (2016)
Fig. 05 Global MRSA Drugs Market Value Share, by Region (2016)
Fig. 06 Key Manufacturers: Comparison Analysis
Fig. 07 Global MRSA Drugs Market Value Share, by Drug Class, 2017 and 2025
Fig. 08 Global MRSA Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Lipopeptide, 2015–2025
Fig. 09 Global MRSA Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Oxazolidinone, 2015–2025
Fig. 10 Global MRSA Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Cephalosporin, 2015–2025
Fig. 11 Global MRSA Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Tetracycline, 2015–2025
Fig. 12 Global MRSA Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Folate Antagonist, 2015–2025
Fig. 13 Global MRSA Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Other Drug Classes, 2015–2025
Fig. 14 Global MRSA Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Lipoglycopeptide, 2015–2025
Fig. 15 Global MRSA Drugs Market Attractiveness, by Drug Class, 2017–2025
Fig. 16 Global MRSA Drugs Market Value Share, by Route of Administration, 2017 and 2025
Fig. 17 Global MRSA Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Oral Route of Administration, 2015–2025
Fig. 18 Global MRSA Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Parenteral Route of Administration, 2015–2025
Fig. 19 Global MRSA Drugs Market Attractiveness, by Route of Administration, 2017–2025
Fig. 20 Global MRSA Drugs Market Value Share, by Distribution Channel, 2017 and 2025
Fig. 21 Global MRSA Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacy, 2015–2025
Fig. 22 Global MRSA Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacy, 2015–2025
Fig. 23 Global MRSA Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Online Pharmacy, 2015–2025
Fig. 24 Global MRSA Drugs Market Attractiveness, by Distribution Channel, 2017–2025
Fig. 25 Global MRSA Drugs Market Value Share, by Region, 2017 and 2025
Fig. 26 Global MRSA Drugs Market Attractiveness, by Region, 2017–2025
Fig. 27 North America MRSA Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2015–2025
Fig. 28 North MRSA Drugs Market Attractiveness, by Country, 2017–2025
Fig. 29 North America MRSA Drugs Market Value Share, by Country, 2017 and 2025
Fig. 30 North America MRSA Drugs Market Value Share, by Drug Class, 2017 and 2025
Fig. 31 North America MRSA Drugs Market Attractiveness, by Drug Class, 2017–2025
Fig. 32 North America MRSA Drugs Market Value Share, by Route of Administration, 2017 and 2025
Fig. 33 North America MRSA Drugs Market Attractiveness, by Route of Administration, 2017–2025
Fig. 34 North America MRSA Drugs Market Value Share, by Distribution Channel, 2017 and 2025
Fig. 35 North America MRSA Drugs Market Attractiveness, by Distribution Channel, 2017–2025
Fig. 36 Europe MRSA Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2015–2025
Fig. 37 Europe MRSA Drugs Market Attractiveness, by Country/Sub-region, 2017–2025
Fig. 38 Europe MRSA Drugs Market Value Share, by Country/Sub-region, 2017 and 2025
Fig. 39 Europe MRSA Drugs Market Value Share, by Drug Class, 2017 and 2025
Fig. 40 Europe MRSA Drugs Market Attractiveness, by Drug Class, 2017–2025
Fig. 41 Europe MRSA Drugs Market Value Share, by Route of Administration, 2017 and 2025
Fig. 42 Europe MRSA Drugs Market Attractiveness, by Route of Administration, 2017–2025
Fig. 43 Europe MRSA Drugs Market Value Share, by Distribution Channel, 2017 and 2025
Fig. 44 Europe MRSA Drugs Market Attractiveness, by Distribution Channel, 2017–2025
Fig. 45 Asia Pacific MRSA Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2015–2025
Fig. 46 Asia Pacific MRSA Drugs Market Attractiveness, by Country/Sub-region, 2017–2025
Fig. 47 Asia Pacific MRSA Drugs Market Value Share, by Country/Sub-region, 2017 and 2025
Fig. 48 Asia Pacific MRSA Drugs Market Value Share, by Drug Class, 2017 and 2025
Fig. 49 Asia Pacific MRSA Drugs Market Attractiveness, by Drug Class, 2017–2025
Fig. 50 Asia Pacific MRSA Drugs Market Value Share, by Route of Administration, 2017 and 2025
Fig. 51 Asia Pacific MRSA Drugs Market Attractiveness, by Route of Administration, 2017–2025
Fig. 52 Asia Pacific MRSA Drugs Market Value Share, by Distribution Channel, 2017 and 2025
Fig. 53 Asia Pacific MRSA Drugs Market Attractiveness, by Distribution Channel, 2017–2025
Fig. 54 Latin America MRSA Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2015–2025
Fig. 55 Latin America MRSA Drugs Market Attractiveness, by Country/Sub-region, 2017–2025
Fig. 56 Latin America MRSA Drugs Market Value Share, by Country/Sub-region, 2017 and 2025
Fig. 57 Latin America MRSA Drugs Market Value Share, by Drug Class, 2017 and 2025
Fig. 58 Latin America MRSA Drugs Market Attractiveness, by Drug Class, 2017–2025
Fig. 59 Latin America MRSA Drugs Market Value Share, by Route of Administration, 2017 and 2025
Fig. 60 Latin America MRSA Drugs Market Attractiveness, by Route of Administration, 2017–2025
Fig. 61 Latin America MRSA Drugs Market Value Share, by Distribution Channel, 2017 and 2025
Fig. 62 Latin America MRSA Drugs Market Attractiveness, by Distribution Channel, 2017–2025
Fig. 63 Middle East & Africa MRSA Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2015–2025
Fig. 64 Middle East & Africa MRSA Drugs Market Attractiveness, by Country/Sub-region, 2017–2025
Fig. 65 Middle East & Africa MRSA Drugs Market Value Share, by Country/Sub-region, 2017 and 2025
Fig. 66 Middle East & Africa MRSA Drugs Market Value Share, by Drug Class, 2017 and 2025
Fig. 67 Middle East & Africa MRSA Drugs Market Attractiveness, by Drug Class, 2017–2025
Fig. 68 Middle East & Africa MRSA Drugs Market Value Share, by Route of Administration, 2017 and 2025
Fig. 69 Middle East & Africa MRSA Drugs Market Attractiveness, by Route of Administration, 2017–2025
Fig. 70 Middle East & Africa MRSA Drugs Market Value Share, by Distribution Channel, 2017 and 2025
Fig. 71 Middle East & Africa MRSA Drugs Market Attractiveness, by Distribution Channel, 2017–2025
Fig. 72 Global MRSA Drugs Market Share, by Company, 2016

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

REQUEST CUSTOMIZATION

Mrsa Drugs Market

Buy Now